Esperion Therapeutics, Inc.

NASDAQ:ESPR

1.65 (USD) • At close September 6, 2024
Bedrijfsnaam Esperion Therapeutics, Inc.
Symbool ESPR
Munteenheid USD
Prijs 1.65
Beurswaarde 323,771,250
Dividendpercentage 0%
52-weken bereik 0.7 - 3.4
Industrie Drug Manufacturers—Specialty & Generic
Sector Healthcare
CEO Mr. Sheldon L. Koenig
Website https://www.esperion.com

An error occurred while fetching data.

Over Esperion Therapeutics, Inc.

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The

Vergelijkbare Aandelen

Tyra Biosciences, Inc. logo

Tyra Biosciences, Inc.

TYRA

20.59 USD

Monte Rosa Therapeutics, Inc. logo

Monte Rosa Therapeutics, Inc.

GLUE

5.69 USD

Belite Bio, Inc logo

Belite Bio, Inc

BLTE

48.2 USD

Regencell Bioscience Holdings Limited logo

Regencell Bioscience Holdings Limited

RGC

6.69 USD

Arcellx, Inc. logo

Arcellx, Inc.

ACLX

71.25 USD

Inotiv, Inc. logo

Inotiv, Inc.

NOTV

1.34 USD

Kodiak Sciences Inc. logo

Kodiak Sciences Inc.

KOD

2.31 USD

MeiraGTx Holdings plc logo

MeiraGTx Holdings plc

MGTX

3.88 USD

Viridian Therapeutics, Inc. logo

Viridian Therapeutics, Inc.

VRDN

14.09 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)